These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8243938)

  • 1. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
    Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
    Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fatal fulminating hepatitis induced by nilutamide].
    Edouard A; Robinel R; Rat C; Lombard F; Lorinet C; Escarmant P
    Gastroenterol Clin Biol; 2003 Dec; 27(12):1170-1. PubMed ID: 14770126
    [No Abstract]   [Full Text] [Related]  

  • 3. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
    Gomez JL; Dupont A; Cusan L; Tremblay M; Tremblay M; Labrie F
    Am J Med; 1992 May; 92(5):563-6. PubMed ID: 1580304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nilutamide-induced acute hepatitis].
    Hammel P; Ducreux M; Bismuth E; Ladouch-Badre A; Benoit G; Buffet C; Etienne JP
    Gastroenterol Clin Biol; 1991; 15(6-7):557. PubMed ID: 1916139
    [No Abstract]   [Full Text] [Related]  

  • 5. Pulmonary complications of hormone treatment in prostate carcinoma.
    Seigneur J; Trechot PF; Hubert J; Lamy P
    Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Jun; 159(6):2099. PubMed ID: 9598539
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
    Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
    Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
    Janknegt RA
    Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fatal fulminating hepatitis caused by nilutamide. A new case].
    Marty F; Godart D; Doermann F; Mérillon H
    Gastroenterol Clin Biol; 1996; 20(8-9):710-1. PubMed ID: 8977826
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers].
    Jonville AP; Diot E; Dutertre JP; Autret E
    Therapie; 1992; 47(5):393-7. PubMed ID: 1299978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nilutamide-induced neutropenia.
    Eaton VS; Blackmore TK
    BJU Int; 2001 Nov; 88(7):801-2. PubMed ID: 11890258
    [No Abstract]   [Full Text] [Related]  

  • 13. Ocular toxicity of Anandron in patients treated for prostatic cancer.
    Harnois C; Malenfant M; Dupont A; Labrie F
    Br J Ophthalmol; 1986 Jun; 70(6):471-3. PubMed ID: 3718913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
    Hucher M; de Gery A; Bertagna C
    Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiandrogen withdrawal syndrome with nilutamide.
    Gomella LG; Ismail M; Nathan FE
    J Urol; 1997 Apr; 157(4):1366. PubMed ID: 9120950
    [No Abstract]   [Full Text] [Related]  

  • 16. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The antiandrogen treatment of patients with prostatic cancer and bone metastases].
    Matveev BP; Bukharkin BV; Zhumagazin ZhD
    Urol Nefrol (Mosk); 1993; (1):10-4. PubMed ID: 7941115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
    Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
    J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of RU 23908 (nilutamide) in prostatic cancer].
    Akaza H; Aso Y; Niijima T; Fuse H; Izaka S; Akimoto S; Shimazaki J; Imai K; Yamanaka H; Kihara K
    Hinyokika Kiyo; 1991 Apr; 37(4):407-20. PubMed ID: 1892002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.